



wherein each occurrence of M is independently  $CV_2$ ,  $-NV-$ ,  $-O-$  or  $-S-$ , wherein each occurrence of V is independently hydrogen, OH, halogen, or aliphatic; each occurrence of Y is independently a covalent bond,  $-O-$ ,  $-S-$  or  $N(R_J)_2$ , wherein  $R_J$ , for each occurrence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl; each occurrence of x is independently 1 or 2; and each occurrence of  $R_1$  is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, a prodrug or pharmaceutically acceptable derivative.

b) Please replace claim 113 with the following amended claim 113:

113. The compound of claim 108 or 112, wherein  $R_C$  is  $-ZR_E$ , wherein Z is  $-O-$ ,  $-S-$ , or  $NR_F$ , wherein  $R_E$  is hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and  $R_F$  is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, whereby at least one of  $R_E$  or  $R_F$  represents a cyclic or acyclic aliphatic or heteroaliphatic moiety, whereby at least one of said cyclic or acyclic aliphatic or heteroaliphatic moieties is substituted by at least one phosphorus moiety.

Sub  
C 20

#### Marked-Up Copies of Claims 108 and 113:

108. The compound of claim 1, wherein  $R_C$  [is defined as above] is cyclic or acyclic aliphatic or heteroaliphatic, or  $-ZR_E$ , wherein Z is  $-O-$ ,  $-S-$ , or  $NR_F$ , wherein  $R_E$  is hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and  $R_F$  is an aliphatic,